Document is current
Any future updates will be listed below
-
Authors
Shaia, Jacqueline K. https://orcid.org/0000-0001-7873-669X
Shukla, Priya
Reed, Hayden https://orcid.org/0009-0003-2577-108X
Kaelber, David C.
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (T32 EY024236)
Research to Prevent Blindness (P30EY025585(BA-A))
Research to Prevent Blindness (P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 17 March 2025
Revised: 15 January 2026
Accepted: 14 April 2026
First Online: 29 April 2026
Competing interests
: RPS reports personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Janssen. KET: Alimera (consultant), AbbVie (consultant), Apellis (consultant), Astellas (Speaker’s bureau), Eyepoint (consultant), Genentech (consultant, speaker’s bureau), Outlook (consultant), Regeneron (consultant, research), Zeiss (speaker, research, consultant). JKS: Impact Education—Regeneron Pharmaceuticals, Inc. The authors declare no competing interests.
